Digestive diseases and sciences

international journal of antimicrobial agents

[1] Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.

[2] The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

[3] antimicrobial resistance and reduced susceptibility in clostridium difficile: potential consequences for induction, treatment, and recurrence of c. difficile infection

[4] characterization of the adherence of clostridium difficile spores: the integrity of the outermost layer affects adherence properties of spores of the epidemic strain r20291 to components of the intestinal mucosa.

[5] clostridium difficile infection outbreak in a male rehabilitation ward, hong kong (china), 2011

[6] the tip of the four n-terminal α-helices of clostridium sordellii lethal toxin contains the interaction site with membrane phosphatidylserine facilitating small gtpases glucosylation

[7] application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection

[8] convergent loss of abc transporter genes from clostridioides difficile genomes is associated with impaired tyrosine uptake and p-cresol production

[9] identification of an essential region for translocation of clostridium difficile toxin b

[10] prevalence of clostridium difficile infection among the patients attending a tertiary care teaching hospital

[11] toxin-specific antibodies for the treatment of clostridium difficile: current status and future perspectives

[12] emergence of community-acquired clostridium difficile infection: the experience of a french hospital and review of the literature

[13] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[14] Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

[15] Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

[16] Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

[17] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

[18] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

[19] National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

[20] An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

[21] Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

[22] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[23] Community-acquired Clostridium difficile infection: an increasing public health threat

[24] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

[25] Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

[26] Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

[27] Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

[28] Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

[29] Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

[30] Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

[31] National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

[32] An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

[33] Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

[34] Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

[35] Community-acquired Clostridium difficile infection: an increasing public health threat

[36] Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

[37] A Novel Quantitative Sampling Technique for Detection and Monitoring of Clostridium difficile Contamination in the Clinical Environment.

[38] Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia

[39] Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.

[40] Clostridium difficile: Is it a new food-borne pathogen?

[41] Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance

[42] The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

[43] Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

[44] Bacterial Diarrhea in HIV-Infected Patients: Why Clostridium difficile, and Why Now?

[45] Clostridium difficile infection in fever patients with gynecological malignancies

[46] Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection

[47] Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

[48] Differences of the Fecal Microflora With Clostridium difficile Therapies

[49] Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship

[50] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

[51] Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients

[52] Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

[53] Epidemiology of community-acquired Clostridium difficile-associated diarrhea

[54] A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

[55] Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study

[56] Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

[57] Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study

[58] Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals

[59] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

[60] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

[61] A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

[62] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

[63] Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection

[64] Prevalence and Pathogenicity of Clostridium difficile in Hospitalized Patients: A French Multicenter Study

[65] Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

[66] Pathway to Prevention of Nosocomial Clostridium difficile Infection

[67] Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

[68] Duodenal infusion of donor feces for recurrent Clostridium difficile

[69] Risk factors for Clostridium difficile toxin-associated diarrhea

[70] John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea

[71] Prevention of Clostridium difficile Infection With Probiotics

[72] Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection

[73] Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

[74] Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients

[75] Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS

[76] Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

[77] Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

[78] Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors

[79] Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea

[80] The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

[81] Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015

[82] pseudomembranous colitis: not always caused by clostridium difficile

[83] antimicrobial resistance and reduced susceptibility in clostridium difficile: potential consequences for induction, treatment, and recurrence of c. difficile infection

[84] antimicrobial use, human gut microbiota and clostridium difficile colonization and infection

[85] severe clostridium difficile infections. a systematic literature -review-

[86] translocation of clostridium difficile toxin b across polarized caco-2 cell monolayers is enhanced by toxin a

[87] characterization of the adherence of clostridium difficile spores: the integrity of the outermost layer affects adherence properties of spores of the epidemic strain r20291 to components of the intestinal mucosa.

[88] clostridium difficile infection outbreak in a male rehabilitation ward, hong kong (china), 2011

[89] applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children

[90] pesquisa utiliza microrganismo clostridium difficile para prevenir infecções em hamsters

[91] biofilm structures in a mono-associated mouse model of clostridium difficile infection

[92] application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection

[93] high mobility group box1 protein is involved in endoplasmic reticulum stress induced by clostridium difficile toxin a

[94] diarrea asociada con infección por clostridium difficile, ¿es tiempo de preocuparnos en méxico?

[95] epidemiological features of clostridium difficile colonizing the intestine of jordanian infants

[96] yersinia infection with clostridium difficile colitis

[97] epidemiological characteristics of nosocomial diarrhea caused by clostridium difficile in a tertiary level hospital in serbia

[98] treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

[99] anaerobically cultivated human intestinal microbiota as first-line treatment for clostridium difficile infection

[100] blastocystis sp. infection mimicking clostridium difficile colitis

[101] refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin